Spyre Therapeutics Inc 2026年季度报告

For the quarterly period ended March 31, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromtoCommission File Number: 001-37722____________________________ SPYRE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)____________________________ 46-4312787(I.R.S. EmployerIdentification No.) Delaware (State or other jurisdiction ofincorporation or organization) 221 Crescent StreetBuilding 23, Suite 105Waltham, MA 02453 Registrant’s telephone number, including area code: (617) 651-5940Former name, former address and former fiscal year, if changed since last report: N/A____________________________ Securities registered pursuant to Section 12(b) of the Exchange Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) ofthe Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant wasrequired to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required tobe submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or forsuch shorter period that the registrant was required to submit such files). YesNoIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “largeaccelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of theExchange Act. Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a)of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YesNo As of April28, 2026, the registrant had 86,841,253 shares of common stock, $0.0001 par value per share,outstanding. SPYRE THERAPEUTICS, INC.QUARTERLY REPORT ON FORM 10-QFOR THE QUARTER ENDED MARCH 31, 2026TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20251Condensed Consolidated Statements of Operations for the Three Months EndedMarch 31, 2026 and 20252Condensed Consolidated Statements of Comprehensive Loss for the Three Months EndedMarch 31, 2026and 20253Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equityfor the Three Months EndedMarch 31, 2026 and 20254Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20256Notes to Unaudited Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations21Item 3.Quantitative and Qualitative Disclosures About Market Risk32Item 4.Controls and Procedures32PART II. OTHER INFORMATION34Item 1.Legal Proceedings34Item 1A.Risk Factors34Item 2.Unregistered Sales of Equity Securities and Use of Proceeds82Item 3.Defaults Upon Senior Securities82Item 4.Mine Safety Disclosures82Item 5.Other Information83Item 6.Exhibits84Signatures86 NOTE ABOUT FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the quarter ended March31, 2026 (this “Quarterly Report”) containsforward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the“Exchange Act”, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”). All statementscontained in this Quarterly Report other than statements of historical fact, including statements regarding any futurepayouts under our contingent value rights (“CVRs”) issued in connection with the acquisition of Spyre Therapeutics, Inc.(the “Asset Acquisition”; our future results of operations and financial position; our business strategy, including our abilityto develop best-in-class therapeutics for inflammatory bowel disease (“IBD”), rheumatoid arthritis (“RA”), psoriatic arthritis(“PsA”), axial spondyloarthritis (“axSpA”) and other immune-mediated diseases that meaningfully improve both efficacyand convenience compared to today's standard of care and our ability to develop first-in-class therapeutics for rheumaticdiseases (“RD”); our plans to expand the development of our product candidates, including SPY002, to indications beyondIBD and RD; our ability to achieve the expected benefits or opportunities with respect to our product candidates, includingtheir potential commercialization; the potential consistency of the SPY001, SPY002, SPY072 an